China Sees Promise, not Danger in Crispr Gene-Editing Trials
publication date: Jan 23, 2018
China researchers have treated 86 cancer patients with genetically modified versions of their own immune cells. Using Crispr-Cas9 tools, the scientists have removed a small section of the patients' T-cell DNA that prevents the immune cells from destroying cancer. There are no similar trials in the US because, according to a Wall Street Journal article (see story), the regulatory systems are so different in the two countries. Until a year ago, China treated cell and gene therapies, particularly autologous cell therapies, as natural substances. Now they are considered drugs and reviewed by the CFDA, which ChinaBio® believes will align China and US regulations more closely. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.